Words by GOLD newsdesk
Genomics has been identified as the most impactful emerging trend in the pharmaceutical industry for 2023, according to results from a new GlobalData survey.
Some 17% of respondents expected genomics to have the greatest impact over the year ahead, particularly in helping to understand, prevent, and treat diseases.
“Genomics has already played a key role in the rapid development, approval, and roll out of the first COVID-19 vaccines, as advancing genomic sequencing allowed scientists to read the COVID-19 genome almost immediately after the virus was identified”, commented Urte Jakimaviciute, Senior Director of Market Research, GlobalData. “The genomics market is expected to exhibit further growth due to rising prevalence of chronic diseases, decreasing sequencing costs, and increasing funding in the area.”
Despite genomics topping the league tables this year, its score was still down 10% compared to data obtained the previous year in the same survey. However, the genomics market is expected to exhibit further growth due to rising prevalence of chronic diseases, decreasing sequencing costs, and increasing funding in the area, according to the analytics company.
Published in GlobalData's 'State of the Biopharmaceutical Industry 2023' report, the survey also highlighted real world evidence (14%) and immune-oncology drug development (14%) as being of particular note for 2023. Remote patient monitoring (13%) and personalised or precision medicines (10%) rounded off the top five.